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Letters to the Editorcolloid used only albumin. These sub-
sequent infusions were provided at the
discretion of the attending physicians.
Dr McKay next asks about blinding
and transfusion practices. This portion
of the protocol is presented in the arti-
cle’s section on Power Analysis. Inten-
sivists providing postoperative care
were blinded to the fluids infused,
but the anesthesiologists infusing the
fluids were not blinded. We followed
this protocol for several reasons. Cur-
rent requirements in this era of regula-
tory compliance call for transparent
intravenous tubing. Given that albu-
min and hetastarch fluids have differ-
ent appearances, it would have been
difficult to assure a blinded process
in the clinical setting of the operating
room even if we had somehow cov-
ered the 500-mL containers from
which the fluid was being infused. Dr
McKay also complains that we do
not present standardized (protocol or
goal-driven) fluid administration. Pre-
suming that Dr McKay is referring to
fluid administered after the first liter
(administered per protocol and de-
scribed in our article’s Statistical
Power Analysis section), we state later
in that section that the remaining stan-
dard operative regimen of crystalloids
and blood products in the periopera-
tive period were administered at the
discretion of the anesthesiologist. We
note in the following paragraphs on
Clinical Protocol that postoperative
fluid management was at the discretion
of the attending intensivist according
to each patient’s clinical status. The
fluid management policy in both pe-
riods was selected so that our study
could examine the impact of the initial
fluid used for volume replacement on
vascular outcome in patients receiving
the careful care provided following the
protocols otherwise used to guide care
in nonresearch environments.
Dr McKay also questions what fac-
tors (beyond infusion of the randomly
assigned fluid) explain the increased
blood loss and transfusion requirement
in members of the hetastarch branch.
She proposes that the 287.2-mLThe Journalgreater infusion of colloid in the initial
preoperative preparation explains the
165.0-mL greater postoperative chest
tube drainage and the 0.73-unit greater
transfusion of packed red blood cells.
The hypothesized mechanism for this
effect is the greater volume of colloid
causing expanded plasma volume,
increased clotting factor dilution, de-
creased blood viscosity, and increased
venous return and cardiac output.
These mechanisms might be believ-
able if the 287.2-mL increase was
from a baseline of 0 mL. Instead, it
represents a 24.1% increase from the
1192.3 mL of colloid administered to
those in the albumin arm (see Table
1). Combining colloid with crystalloid
and cell salvage, those in the hetas-
tarch arm were infused with 4944.9
mL while those in the albumin arm
were infused with 4693.7 mL, a differ-
ence of 251.4 mL or 5.4% of the vol-
ume of fluids administered in the
perioperative period. We do not think
this 5.4% difference in fluid adminis-
tered is clinically significant. We also
note that albumin was the only fluid
administered after the first liter.
We agree with Dr McKay that the
question of which fluids should be con-
sidered optimal for volume replace-
ment in CABG procedures is not
settled. We are now actively involved
in designing further studies using asso-
ciations with the outcomes examined
in our study and other outcomes to ex-
amine the effectiveness and risks of us-
ing albumin versus other fluids in this
clinical context. We trust that these
and other studies will provide a meth-
odologically sound evidence base that
can be used to guide future clinical de-
cision-making in this area.
Howard Barkan, DrPH
University of California
Berkeley, Calif
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ABNORMALITIES AND
SCARRING IN SEVERE
FUNCTIONAL ISCHEMIC
MITRAL REGURGITATION:
A PILOT CARDIOVASCULAR
MAGNETIC RESONANCE
IMAGING STUDY
To the Editor:
We read with interest Flynn and col-
leagues’ article1 concerning preopera-
tive evaluation with cardiac magnetic
resonance imaging (MRI) in patients
undergoing coronary artery bypass
grafting and mitral valve annuloplasty
for ischemic mitral valve regurgitation
(IMVR).
In our experience, cardiac MRI has
been advocated for preoperative rou-
tine evaluation of patients withry c Volume 139, Number 3 795
Letters to the EditorIMVR since 2006.2 In a cohort of pa-
tients with coronary artery disease
and depressed left ventricular ejection
fraction, IMVR seemed to occur
mainly whenever a transmural area of
delayed enhancement (necrosis) was
present at cardiac MRI within the infe-
rior myocardial segments.3
On the contrary, we did not notice
any significant difference in the geo-
metric mitral valve and papillary mus-
cle parameters (as documented at MRI)
when comparing patients with and
without IMVR. Furthermore, myocar-
dial necrosis distribution was the sole
determinant for IMVR occurrence.3
This confirms that IMVR is not
resulting from an abnormal valve/ap-
paratus but from a malfunctioning
ventricular muscle (in its segmental
aspects), and for this reason, surgical
decision making cannot be adequately
performed just on the basis of a simple
rest echocardiography.
We agree with Flynn and colleagues1
that patients with excessive scar burden
(at MRI) in the inferior myocardial seg-
ments (particularly those segments
close to the posterior papillary muscles)
will possibly have recurrent IMVR even
after annuloplasty. Within this group of
patients, we think some distinctions
should be made. In fact, in our surgical
practice we still perform a simple annu-
loplasty if a segmental geometric re-
modeling has not yet taken place and
vital areas are present within the de-
layed enhancement (necrotic) zone. In
this case, we should emphasize that
standard MRI will not be able to detect
hibernated myocardium that could,
once the coronary target has been revas-
cularized, prevent the geometric remod-
eling and the consequent IMVR
recurrence.
In this context, dynamic echocardi-
ography (with dobutamine or semi-su-
pine physical stress) may assist in
further surgical stratification and iden-
tification of ‘‘recoverable’’ myocar-
dium.
In a different context, identification
of large areas of MRI delayed en-
hancement in the inferior myocardium796 The Journal of Thoracic and Cshould trigger further evaluation even
in patients with mild IMVR. In partic-
ular, physical stress echocardiography
may enhance severe IMVR even in
patients with mild regurgitation at
rest.4 This finding could support
a broader application of mitral valve
annuloplasty, especially when the
myocardial remodeling has not yet
taken place.
In conclusion, together with Flynn
and colleagues,1 we agree that IMVR
is an elusive occurrence and adequate
surgical stratification cannot be per-
formed with sole rest echocardiogra-
phy. IMVR is a disease of the
ventricular muscle, and surgical out-
comes should be reinterpreted in the
light of preoperative evaluation with
global morphofunctional and perfu-
sion-vitality studies, such as those
achievable with MRI. The presence
of extensive necrosis in the inferior
myocardial segments may suggest
a high rate of postoperative IMVR re-
currence. Further investigation with
preoperative stress echocardiography
may identify viable myocardium and
trigger IMVR in those patients with
mild regurgitation at rest. In both
cases, myocardial surgical revasculari-
zation together with mitral valve annu-
loplasty may be a valid option if
adequate coronary targets are present
and myocardial remodeling has not
yet taken place.
Giuseppe D’Ancona, MD
Michele Pilato
Department of CT Surgery
ISMETT (Mediterranean Institute for
Transplantation and Advanced
Specialized Therapies)
Palermo, Italy
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We thank Drs D’Ancona and Pilato for
their thoughtful comments. Patients
with ischemic cardiomyopathy repre-
sent a diverse population who differ
in the extent of myocardial ischemia,
severity of the left ventricular dysfunc-
tion, and severity of functional ische-
mic mitral regurgitation. A thorough
understanding of the extent of ischemic
changes is essential for the appropriate
planning of surgical therapy. Magnetic
resonance imaging has emerged as
a powerful diagnostic tool for the com-
prehensive evaluation of patients with
ischemic cardiomyopathy. In our prac-
tice, magnetic resonance imaging is
routinely used in patients with ische-
mic cardiomyopathy for the assess-
ment of the severity and distribution
of myocardial scarring, as well as the
estimation of residual myocardial via-
bility. Severity of ischemic changes de-
termines the choice of surgical therapy.
Presence of transmural scarring in the
region of the papillary muscles in pa-
tients with severe ischemic cardiomy-
opathy and severe functional mitral
regurgitation is a poor prognostic sign
indicating advanced disease. Myocar-
dial revascularization and mitral valve
repair with an undersized annuloplasty
ring in these patients are often associ-
ated with the poor outcomes and high
incidence of recurrent mitral regurgita-
tion; therefore, alternative therapies, in-
cluding heart transplantation, should be
considered.1 In contrast, in patients with
less severe forms of ischemic cardiomy-
opathy and moderate functional ische-
mic regurgitation, substantial
improvement in functional status and
survival can be accomplished with iso-
lated coronary artery bypass grafting.2
